Table 3.
Comparison of the phenotypic characteristics between TGCT patients with and without gr/gr deletion, partial AZFc duplications and DAZ dosage alteration. a) Histology and semen phenotype; b) testis volume, hormonal dosage and clinical risk factors. The frequency between subgroups did not result significantly different for any of the analyzed parameters
| (a) | gr/gr deletion | Partial AZFc duplications | DAZ dosage alteration | |||
|---|---|---|---|---|---|---|
| No (n = 483) | Yes (n = 14) | No (n = 456) | Yes (n = 22) | No (n = 446) | Yes (n = 51) | |
| Histology | ||||||
| Seminoma | 342 (70.8%) | 11 (78.6%) | 322 (70.6%) | 16 (72.7%) | 315 (70.6%) | 38 (74.5%) |
| Non-seminoma | 141 (29.2%) | 3 (21.4%) | 134 (29.4%) | 6 (27.3%) | 131 (29.4%) | 13 (25.5%) |
| Semen parameters. Median value (minimum-maximum) | ||||||
| Volume (ml) | 3.2 (0.3–10.5) | 3.6 (1.8–5.9) | 3.2 (0.3–10.5) | 3.0 (1.0–5.9) | 3.2 (0.3–10.5) | 3.2 (1.0–5.9) |
| Sperm Concentration (106/ml) | 14.9 (0–336.0) | 30.0 (0–100.0) | 15.0 (0–336.0) | 7.0 (0–125.0) | 15.0 (0–336.0) | 21.0 (0–125.0) |
| Total sperm count (106) | 47.3 (0–915.9) | 94.2 (0–720.0) | 48.3 (0–915.9) | 30.0 (0–375.0) | 46.5 (0–915.9) | 63.0 (0–720.0) |
| Progressive motility (%) | 47.0 (0–81.0) | 44.0 (0–84.0) | 47.0 (0–81.0) | 41.0 (0–69.0) | 47.0 (0–81.0) | 40.5 (0–84.0) |
| Total motile sperm count (106) | 19.6 (0–650.3) | 41.2 (0–316.8) | 19.6 (0–650.3) | 10.3 (0–258.8) | 19.4 (0–650.3) | 37.4 (0–316.8) |
| Normal morphology (%) | 8.0 (0–47.0) | 7.0 (0–35.0) | 8.0 (0–47.0) | 6.0 (0–33.0) | 8.0 (0–47.0) | 6.0 (0–35.0) |
| Semen phenotype | ||||||
| Normozoospermic | 259 (53.6%) | 9 (64.3%) | 247 (54.2%) | 9 (40.9%) | 240 (53.8%) | 28 (54.9%) |
| Non-normozoospermic | 224 (46.4%) | 5 (35.7%) | 209 (45.8%) | 13 (59.1%) | 206 (46.2%) | 23 (45.1%) |
| (b) | gr/gr deletion | Partial AZFc duplications | DAZ dosage alteration | |||
|---|---|---|---|---|---|---|
| No (n = 361) | Yes (n = 11) | No (n = 348) | Yes (n = 11) | No (n = 338) | Yes (n = 34) | |
| Testis volume (ml), Median value (minimum-maximum) | ||||||
| Right testis (ml) | 20.0 (8.0–30.0) | 22.0 (18.0–30.0) | 20.0 (8.0–30.0) | 17.5 (8.0–25.0) | 20.0 (8.0–30.0) | 18.0 (8.0–30.0) |
| Left testis (ml) | 20.0 (7.0–30.0) | 19.0 (8.0–25.0) | 19.0 (7.0–30.0) | 20.0 (12.0–25.0) | 20.0 (7.0–30.0) | 19.5 (8.0–25.0) |
| Hormonal analysis. Median value (minimum-maximum)a | ||||||
| LH (mU/ml) | 5.9 (1.9–25.5) | 5.7 (1.5–11.2) | 6.1 (1.9–25.5) | 5.0 (2.4–8.0) | 5.9 (1.9–22.5) | 5.5 (1.5–25.5) |
| FSH (mU/ml) | 9.7 (1.4–45.7) | 6.7 (3.7–28.6) | 9.9 (1.4–45.7) | 7.2 (2.3–12.9) | 9.9 (1.4–45.7) | 7.2 (1.5–42.2) |
| Testosterone (nmol/l) | 14.1 (4.4–33.6) | 18.8 (15.8–24.8) | 14.1 (4.4–33.6) | 13.1 (5.9–23.1) | 14.3 (4.4–33.6) | 14.8 (5.9–24.8) |
| Family history of TGCT | 4 (1.1%) | 0 (0.0%) | 4 (1.2%) | 0 (0%) | 4 (1.2%) | 0 (0%) |
| Cryptorchidism | 54 (15.0%) | 3 (27.3%) | 53 (15.2%) | 0 (0%) | 53 (15.7%) | 4 (11.8%) |
| Hypospadias | 3 (0.8%) | 0 (0.0%) | 3 (0.9%) | 0 (0%) | 3 (0.9%) | 0 (0%) |
aPatients with a choriocarcinoma component in their testis histology were excluded (n = 29)